The US dispute with Germany over drug prices is now a formal trade case. On 18 June 2026 the US Trade Representative opened a Section 301 investigation into what it calls Germany's "persistent underpayment" for innovative medicines. The tools it names are the ones launch teams rely on in Germany, so the case affects pricing plans well beyond the political headlines.

What USTR is investigating

Section 301 of the Trade Act of 1974 lets USTR examine foreign practices it considers unreasonable or discriminatory toward US commerce. Here the stated concern is that US patients carry a disproportionate share of global pharmaceutical R&D costs. USTR says the notice follows months of discussions with Germany, and it has requested formal consultations.

Two mechanisms are named: supplemental discounts granted in exchange for keeping negotiated prices confidential, and mandatory variable-rate rebates. According to a legal analysis of the notice, the confidentiality route requires a 9% price discount plus administrative costs, and rebate legislation would add mandatory rebates on patented medicines from 2027.

Comments and hearing requests were due on 10 August, and the public hearing was set for 22 September 2026. USTR has also pointed to the pricing arrangement the US and UK announced on 2 April 2026 and said Germany should follow with "constructive negotiations".

Why the confidential price matters

The confidentiality option comes from Germany's Medizinforschungsgesetz (MFG). A company that meets a local R&D requirement can keep a discounted price confidential, and agrees to a 9% discount on its negotiated net price. LCP Health Analytics described it as a way to hold the public list price steady while net prices stay low. That matters because the US most-favoured-nation (MFN) approach references the lowest price in a basket of countries without weighing added clinical benefit. Lilly was the first company to use the new provisions for an innovative drug, Mounjaro, which had received no additional benefit in most cases under AMNOG, the German early benefit assessment.

USTR now lists that same confidentiality route as part of the problem. A mechanism designed to protect list prices from international reference pricing has become a trade target.

The German payer position

The statutory insurers have no appetite to pay more. In a March 2026 statement, the GKV-Spitzenverband (GKV-SV) said the industry should share in system-wide savings and that prices can fall "ohne die Industrie zu vertreiben" (without driving the industry out). Its chair, Oliver Blatt, said German prices are already the highest after those of the USA. Health Minister Nina Warken said the insurers' tight finances make higher prices hard to pay, as Deutsches Ärzteblatt reported.

That leaves Germany between a payer side committed to lower prices and a trade partner demanding higher ones. Trade policy is also an EU competence, so Germany cannot strike a bilateral tariff deal. The UK settled in April by agreeing to raise prices for patented medicines, with an effective discount on new drugs capped at 16% under VPAG. In return, UK manufacturers were protected from tariffs for three years. Germany has no equivalent route.

What it means for market access teams

  • Treat the German net price as a reference point. Whether the confidential option stays available, and on what terms, is now a negotiating item. Model launches both with and without it.
  • Revisit launch sequencing. Germany has been an early launch market because of free pricing in the first six months. LCP's authors say MFN could push companies towards US-first launches and more selective follow-on markets. A weaker German price position strengthens that case.
  • Plan for a larger rebate burden from 2027. The rebate legislation is the other target in the notice. Budget scenarios should include it, and its final terms should be checked before forecasts are locked.
  • Keep the AMNOG evidence strong. A clear added benefit is still the best protection for the negotiated price, whatever happens to the confidentiality route.

We expect the outcome to depend on how the investigation interacts with the Section 232 tariffs on patented pharmaceuticals, which push manufacturers towards MFN agreements with HHS. The legal analysis cited above calls the two a coordinated "pincer".

To discuss how this affects your German launch price and sequencing, get in touch.